Legal/Regulatory Proceedings
Aurobindo Pharma Facility Receives US FDA OAI Classification
Aurobindo Pharma said the US FDA classified its Lannett Company facility in Seymour, Indiana as Official Action Indicated after an August inspection.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
1
Neutral
8
Bullish
5
Bearish
10
Neutral
8
Bullish
28
Bearish
9
Neutral
0
Bullish
23
Bearish
9
Neutral
0
Bullish
23
Bearish
9
Neutral
0
Bullish
23
Bearish
9
Neutral
0
Bullish
23
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone

Legal/Regulatory Proceedings
Aurobindo Pharma said the US FDA classified its Lannett Company facility in Seymour, Indiana as Official Action Indicated after an August inspection.
Earnings Call/Transcript
Aurobindo Pharma submitted the transcript of its Q2 FY27 earnings call held on November 5, 2026, covering financial performance and business outlook.
Legal/Regulatory Proceedings
Aurobindo Pharma’s subsidiary Apitoria Pharma Unit 2 received a US FDA Establishment Inspection Report classifying the facility as Voluntary Action Indicated. The inspection was closed under 21 CFR 20.64(d)(3).

Pharmaceuticals & Biotechnology
Pharmaceuticals
1,03,689 Cr
Low Risk
26.0
39.0
1.7
2.6
1,856.70
1,106.25
Sales CAGR
Profit CAGR
ROE
ROCE
Aurobindo Pharma Ltd (AUROPHARMA) is currently trading at 1,802.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aurobindo Pharma develops, manufactures, and markets APIs, intermediates, generic formulations, biosimilars, specialty products, vaccines, and contract-manufacturing services across more than 150 countries. Its integrated model spans formulation manufacturing, APIs, regulated-market filings, complex generics, biologics, and emerging CRDMO capabilities, supported by 29 manufacturing plants and nine R&D facilities. Aurobindo Pharma delivered its highest-ever quarterly revenue of INR 10,263 crore in Q2 FY27, up 24% year over year, while operating EBITDA rose 28% to INR 2,156 crore. The 21% EBITDA margin improved despite higher input and freight costs, indicating operating leverage, favorable product mix, and stronger performance across Europe, the United States, and other businesses. Aurobindo Pharma’s growth strategy is shifting toward complex and higher-value products. Generic Advair launched during the quarter, generic QVAR received approval, ADQUEY became the company’s first new chemical entity/NDA product, and respiratory, dermatology, biosimilars, and specialty products are being developed as longer-term margin and differentiation drivers. The Lannett acquisition is already profitable and integrating ahead of expectations, although its manufacturing footprint remains underutilized. Aurobindo Pharma intends to improve utilization selectively through new products and CDMO opportunities, while avoiding low-margin volume merely to fill capacity. Aurobindo Pharma’s financial flexibility remains strong, with quarterly cash flow of USD 146 million and a closing net cash position of USD 189 million. The company is simultaneously funding acquisitions, product development, biologics, CRDMO capabilities, and manufacturing expansion while maintaining disciplined capital allocation and working-capital management.
Over the past 52 weeks, Aurobindo Pharma Ltd has traded between a low of ₹1,106.25 and a high of ₹1,856.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aurobindo Pharma Ltd has a market capitalization of approximately 1,03,145.12. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aurobindo Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.87 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,03,145.12 Cr, Aurobindo Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aurobindo Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aurobindo Pharma Ltd is 25.87. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Aurobindo said it does not intend to copy the molecule-count ambitions of Sandoz or Fresenius Kabi. Management said programmes of 100 or 37 biosimilars require years of sustained investment in development, manufacturing and commercial infrastructure through a long-term horizon such as 2040.
Yes. Aurobindo said Lannett is profitable at its present operating level despite its underutilised facilities. The company did not provide a revenue figure, profit amount or margin for the business on 5 November 2026.
Aurobindo Pharma reported consolidated revenue of Rs 10,263 crore for Q2 FY27. This was its highest quarterly revenue and represented 24% year-on-year growth from Rs 8,286 crore.
Aurobindo Pharma reported consolidated profit after tax of Rs 1,123.84 crore for the quarter ended September 30, 2026. This was Rs 275.71 crore higher than Rs 848.13 crore in the corresponding quarter of 2025.